Sturamustine
Sturamustine[edit]
Sturamustine is a chemotherapy drug that belongs to the class of alkylating agents. It is primarily used in the treatment of certain types of cancer, including prostate cancer and breast cancer. Sturamustine is a nitrogen mustard derivative, which means it works by interfering with the DNA replication process in cancer cells, ultimately leading to cell death.
Mechanism of Action[edit]
Sturamustine functions by forming cross-links between DNA strands, which prevents the DNA from being properly replicated and transcribed. This action is typical of alkylating agents, which are known for their ability to add alkyl groups to the DNA molecule. The cross-linking of DNA strands inhibits the cell cycle, particularly affecting rapidly dividing cancer cells.
Clinical Use[edit]
Sturamustine is used in the treatment of hormone-refractory prostate cancer and breast cancer that has not responded to other forms of treatment. It is often administered in combination with other chemotherapy agents to enhance its effectiveness. The drug is typically given intravenously, and the dosage depends on the patient's overall health, the type of cancer, and the stage of the disease.
Side Effects[edit]
Like many chemotherapy drugs, Sturamustine can cause a range of side effects. Common side effects include nausea, vomiting, hair loss, and myelosuppression, which is a decrease in the production of blood cells. Patients may also experience fatigue, diarrhea, and an increased risk of infection due to lowered white blood cell counts.
Pharmacokinetics[edit]
Sturamustine is metabolized in the liver and excreted primarily through the kidneys. The drug's half-life and clearance rate can vary depending on the patient's liver function and renal function. Monitoring of blood cell counts and liver function tests is essential during treatment to adjust dosages and prevent toxicity.
Research and Development[edit]
Ongoing research is focused on improving the efficacy and reducing the side effects of Sturamustine. Studies are exploring its use in combination with newer targeted therapies and immunotherapy agents. Researchers are also investigating the molecular mechanisms underlying resistance to Sturamustine in certain cancer types.
Related Pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
